News headlines about Macrocure (NASDAQ:MCUR) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Macrocure earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9411282181772 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Macrocure (MCUR) Share Price” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/10/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-macrocure-mcur-share-price-2.html.

Macrocure Company Profile

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.

Insider Buying and Selling by Quarter for Macrocure (NASDAQ:MCUR)

Receive News & Stock Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related stocks with our FREE daily email newsletter.